Nymox Pharmaceutical Corp (NYMX) Reports Q1 EPS of $0.07

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/6/2026

1. USO
2. MRVL
3. SPY
4. NVDA
5. BBIO
6. GOOGL
7. OPCH
8. AMD
9. CHRW
10. APLD

Go back to Nymox Pharmaceutical Corp (NYMX) Reports Q1 EPS of $0.07

Nymox Pharma (NYMX) Issues Positive Update on NX-1207 Phase 2 in Prostate Cancer

May 13, 2014 9:46 AM EDT

Nymox Pharmaceutical Corporation (Nasdaq: NYMX) reported positive new study findings showing that the Company's NX-1207 Phase 2 treatment for localized low-risk prostate cancer did not affect testosterone levels in treated men. Analysis of testosterone levels post-treatment for men treated with NX-1207 2.5 mg (n=47) or 15 mg (n=46) showed no statistically significant change as compared to control active surveillance patients (n=48). This data is consistent with the large body of existing data for men... More